Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., Vogelstein, B.·1992·Nature
DOI 10.1038/358080a0

Cited by (1,001)

Items 501–600 of 1,001

  1. Chromosome instability in cancer:how, when, and why?
    David Gisselsson · 2003 · Advances in cancer research
  2. Application of Comparative Genomic Hybridization, Spectral Karyotyping, and Microarray Analysis in the Identification of Subtype-Specific Patterns of Genomic Changes in Rhabdomyosarcoma
    Ajay Pandita, Maria Zieleńska, Paul Thomer, Jane Bayani, Roseline Godbout, Mark Greenberg, Jeremy Andrew Squire · 1999 · Neoplasia
  3. The MDM2 gene family
    Michael J. Mendoza, Garni Mandani, Jamil Antonio Momand · 2013 · BioMolecular Concepts
  4. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas
    Yasmine A. Valentin-Vega, Juan Barboza, Gilda P. Chau, Adel K. El‐Naggar, Guillermina Lozano · 2007 · Human Pathology
  5. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands
    Tamotsu Kiyoshima, Kaori Shima, Ieyoshi Kobayashi, Keitaro Matsuo, Kazuhiko Okamura, S Komatsu, Abu Mohammad Eahsan Rasul, H Sakai · 2001 · Oral Oncology
  6. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor
    Alexander H. Stegh, Cameron Brennan, John E. Mahoney, Kristin L. Forloney, Harry T. Jenq, Janina P. Luciano, Alexei I. Protopopov, Lynda Chin, Ronald Anthony DePinho · 2010 · Genes & Development
  7. Grading in soft tissue tumors: principles and problems
    Antonio G. Nascimento, André M. Oliveira · 2001 · Skeletal Radiology
  8. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
    Carolyn Cao, Eric T. Shinohara, Ty K. Subhawong, Ling Geng, Kwang Woon Kim, Jeffrey M. Albert, Dennis E. Hallahan, Bo Lü · 2006 · Molecular Cancer Therapeutics
  9. Soft Tissue Sarcoma
    Raphael E. Pollock · 1999 · Seminars in Surgical Oncology
  10. Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
    Weisi Wang, Yongzhou Hu · 2011 · Medicinal Research Reviews
  11. Compilation of somatic mutations of theCDKN2 gene in human cancers: Non-random distribution of base substitutions
    Pamela M. Pollock, John V. Pearson, Nicholas K. Hayward · 1996 · Genes Chromosomes and Cancer
  12. Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction
    Ana Z. González, John E. Eksterowicz, Michael D. Bartberger, Hilary P. Beck, Jude R. Canon, Ada Chen, David T. Chow, Jason Duquette, Brian M. Fox, Jiasheng Fu et al. · 2014 · Journal of Medicinal Chemistry
  13. Versatile functions of p53 protein in multicellular organisms
    Peter M. Chumakov · 2007 · Biochemistry (Moscow)
  14. Radiation-induced Genomic Instability
    A. Kronenberg · 1994 · International Journal of Radiation Biology
  15. Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line
    Midori Saito, Kristian Helin, Marcus B. Valentine, Barbara B. Griffith, Cheryl L. Willman, Ed Harlow, Alfred Thomas Look · 1995 · Genomics
  16. Cancer risks from germline p53 mutations.
    Thierry Frébourg, Stephen Henry Friend · 1992 · Journal of Clinical Investigation
  17. Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
    Gonzalez-Lopez de Turiso, Felix, Sun, Daqing, Rew, Yosup, Bartberger, Michael D., Beck, Hilary P., Canon, Jude, Chen, Ada, Chow, David, Correll, Tiffany L., Huang, Xin et al. · 2013 · Journal of Medicinal Chemistry
  18. Identification of the Spiro(oxindole-3,3′-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators
    Isabel Maria Gomez-Monterrey, Alessia Bertamino, Amalia Porta, Alfonso Carotenuto, Simona Musella, Claudio Aquino, Ilaria Granata, Marina Sala, Diego Brancaccio, Delia Picone et al. · 2010 · Journal of Medicinal Chemistry
  19. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction
    Orazio Fortunato, Mattia Boeri, Massimo Moro, Carla Verri, Mavis Mensah, Davide Conte, Laura Caleca, Luca Roz, Ugo Pastorino, Gabriella Sozzi · 2014 · Cell Death and Disease
  20. Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells
    Te‐Ling Lu, Guan‐Jhong Huang, Te‐Jung Lu, Jin-Bin Wu, Chieh‐Hsi Wu, Tung‐Chuan Yang, Akira Iizuka, Yuh-Fung Chen · 2009 · Food and Chemical Toxicology
  21. The MDM2 C-terminal Region Binds to TAFII250 and Is Required for MDM2 Regulation of the Cyclin A Promoter
    Thierry Léveillard, Bohdan Wasylyk · 1997 · Journal of Biological Chemistry
  22. HSP70 Binding Sites in the Tumor Suppressor Protein p53
    Anne M. Fourie, Ted R. Hupp, David Philip Lane, Bi‐Ching Sang, Miguel S. Barbosa, Joseph Sambrook, Mary-Jane H. Gething · 1997 · Journal of Biological Chemistry
  23. The mdm-2 Oncogene Can Overcome Wild-Type p53 Suppression of Transformed Cell Growth
    Cathy A. Finlay · 1993 · Molecular and Cellular Biology
  24. Overexpression of the<i>MDM2</i>Oncogene in Leukemia and Lymphoma
    Watanabe, Takashi, Ichikawa, Atsushi, Saito, Hidehiko, Hotta, Tomomitsu · 1996 · Leukemia &amp; Lymphoma
  25. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation
    Jackson, Mark W., Lindström, Mikael S., Berberich, Steven J. · 2001 · Journal of Biological Chemistry
  26. The expression of iASPP in acute leukemias
    Xinwei Zhang, Min Wang, Chunlin Zhou, Sen Chen, Jianxiang Wang · 2004 · Leukemia Research
  27. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase
    Michael Hsiao, Alice Lin-Tsing Yu, Jo Yeargin, D Ku, Martin Haas · 1994 · Blood
  28. p53--An Acrobat in Tumorigenesis
    Ute Martha Moll, Laura Schramm · 1998 · Critical Reviews in Oral Biology & Medicine
  29. Small Molecule Inhibition of HDM2 Leads to p53-Mediated Cell Death in Retinoblastoma Cells
    Jasmine R. Elison · 2006 · Archives of Ophthalmology
  30. Genetic and Molecular Markers of Urothelial Premalignancy and Malignancy
    Carlos Cordon‐Cardo, Richard J. Côté, Guido Sauter · 2000 · Scandinavian Journal of Urology and Nephrology
  31. Twelve amplified and expressed genes localized in a single domain in glioma
    Ulrike Fischer, Paul S. Meltzer, Eckart U. Meese · 1996 · Human Genetics
  32. Interaction of Human T-cell Lymphotropic Virus Type I Tax, Ets1, and Sp1 in Transactivation of the PTHrP P2 Promoter
    Jürgen Dittmer, Cynthia A. Pise-Masison, Karen E. Clemens, Kyeong Sook Choi, John N Brady · 1997 · Journal of Biological Chemistry
  33. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
    Eischen, Christine M., Lozano, Guillermina · 2014 · Human Mutation
  34. Computational studies and peptidomimetic design for the human p53–MDM2 complex
    Haizhen A. Zhong, Heather A. Carlson · 2004 · Proteins Structure Function and Bioinformatics
  35. Nitric oxide induces phosphorylation of p53 and impairs nuclear export
    Nicole Schneiderhan‐Marra, Andreja Budde, Yanping Zhang, Bernhard Brüne · 2003 · Oncogene
  36. p53-Induced Apoptosis as a Safeguard against Cancer
    Charlotte Asker, Klas G. Wiman, Galina Selivanova · 1999 · Biochemical and Biophysical Research Communications
  37. Patented small molecule inhibitors in the ubiquitin proteasome system
    Philippe Guédat, Frédéric Colland · 2007 · BMC Biochemistry
  38. Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing’s and Osteogenic Sarcoma Models
    Pedro J. Beltran, Young-Ah Chung, Gordon E. Moody, Petia Mitchell, Elaina E Cajulis, Steven L. Vonderfecht, Richard L. Kendall, Robert Radinsky, Frank J. Calzone · 2011 · Journal of Pharmacology and Experimental Therapeutics
  39. Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1)
    Seiji Kondo, Ying Lu, Michael E. Debbas, Athena W. Lin, Ildiko Sarosi, Annick Itié, Andrew C. Wakeham, JoAnn Tuan, Chris J. M. Saris, Gary Elliott et al. · 2003 · Proceedings of the National Academy of Sciences
  40. p53 and p21 Determine the Sensitivity of Noscapine-Induced Apoptosis in Colon Cancer Cells
    Ritu Aneja, Amr M. Ghaleb, Jun Zhou, Vincent W. Yang, Harish Chandra Joshi · 2007 · Cancer Research
  41. Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles
    Angelo Aguilar, Wei Sun, Liu Liu, Jianfeng Lu, Donna McEachern, Denzil Bernard, Jeffrey R. Deschamps, Shaomeng Wang · 2014 · Journal of Medicinal Chemistry
  42. p53 and K-ras Mutational Genotyping in Pulmonary Carcinosarcoma, Spindle Cell Carcinoma, and Pulmonary Blastoma: Implications for Histogenesis
    Valerie A. Holst, Sydney David Finkelstein, Thomas Vail Colby, Jeffrey L. Myers, Samuel A. Yousem · 1997 · The American Journal of Surgical Pathology
  43. Genetic Aberrations in Human Brain Tumors
    Steven P. Leon, Jiguang Zhu, Peter McL. Black · 1994 · Neurosurgery
  44. Deletion in Human Chromosome Region 12q13-15 by Integration of Human Papillomavirus DNA in a Cervical Carcinoma Cell Line
    Marta Ines Gallego, Pedro A. Lazo · 1995 · Journal of Biological Chemistry
  45. Translational approaches targeting the p53 pathway for anti‐cancer therapy
    Essmann, Frank, Schulze‐Osthoff, Klaus · 2012 · British Journal of Pharmacology
  46. Small-Molecule Inhibitors of the p53-MDM2 Interaction
    Binh Thanh Vu, Lyubomir T. Vassilev · 2010 · Current topics in microbiology and immunology
  47. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy
    Louis Lacombe, Alain Maillette, François Meyer, Chantal Veilleux, Lynne Moore, Yves Fradet · 2001 · International Journal of Cancer
  48. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
    Hege Oma Ohnstad, Erik B. Paulsen, Paul Noordhuis, Marianne Berg, Ragnhild A. Lothe, Lyubomir T. Vassilev, Ola Myklebost · 2011 · BMC Cancer
  49. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population
    Hongxia Ma, Zhibin Hu, Xiangjun Zhai, Shui Wang, Xuechen Wang, Jianwei Qin, Guangfu Jin, Jiyong Liu, Xinru Wang, Qingyi Wei et al. · 2005 · Cancer Letters
  50. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers
    Francesco Bertoni, Anna Maria Codegoni, Daniela Furlan, Maria Grazia Tibiletti, Carlo Capella, Massimo Broggini · 1999 · Genes Chromosomes and Cancer
  51. p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue
    Christopher Paul Wild, Maaret Ridanpää, Sisko L. Anttila, Richard Lubin, Thierry Soussi, Kirsti Husgafvel‐Pursiainen, Harri Vainio · 1995 · International Journal of Cancer
  52. Active transforming growth factor-β in human melanoma cell lines: No evidence for plasmin-related activation of latent TGF-β
    Jozef Bízik, Diana Felnerova, Marta Grofova, Antti I. Vaheri · 1996 · Journal of Cellular Biochemistry
  53. MDM2 Integrates Cellular Respiration and Apoptotic Signaling through NDUFS1 and the Mitochondrial Network
    Rana Elkholi, Ioana Abraham‐Enachescu, Andrew Paul Trotta, Camila Rubio‐Patiño, Jarvier N. Mohammed, Mark P.A. Luna‐Vargas, Jesse D. Gelles, Joshua R. Kaminetsky, Madhavika N. Serasinghe, Cindy Zou et al. · 2019 · Molecular Cell
  54. Analysis of Ki-ras, p53, and MDM2 Genes in Uterine Leiomyomas and Leiomyosarcomas
    Kevin L. Hall, Michael G. Teneriello, Robert R. Taylor, Stephen J. Lemon, Masahito Ebina, R. Ilona Linnoila, J.Henry Norris, Robert C. Park, Michael J. Birrer · 1997 · Gynecologic Oncology
  55. Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator
    Xiang Yu Zhou, Qian Hao, Peng Liao, Shiwen Luo, Minhong Zhang, Guohui Hu, Hongbing Liu, Yi-Wei Zhang, Bo Cao, Melody Baddoo et al. · 2016 · eLife
  56. c-Myc, Genome Instability, and Tumorigenesis: The Devil Is in the Details
    Mark R. Wade, Geoffrey M. Wahl · 2006 · Springer eBooks
  57. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis
    Gitali Ganguli, Joseph Abecassis, Bohdan Wasylyk · 2000 · The EMBO Journal
  58. Overexpression and Localization of Heat Shock Proteins mRNA in Pancreatic Carcinoma
    Masao Ogata, Zenya Naito, Shigeo Tanaka, Yuhkichi Moriyama, Gorô Asano · 2000 · Journal of Nippon Medical School
  59. Immunoreactivity for p53 protein in malignant mesothelioma and non‐neoplastic mesothelium
    Marc Ramael, Greet Lemmens, Christa Eerdekens, Corinne M.P. Buysse, Ivo Deblier, Werner Jacobs, Eric Van Marck · 1992 · The Journal of Pathology
  60. Apoptosis-associated proteins and the development of oral squamous cell carcinoma
    Michael L Schoelch, Quynh‐Thu Le, S Silverman, Alex McMillan, N. Dekker, K.K Fu, Barry L. Ziober, Joseph A. Regezi · 1999 · Oral Oncology
  61. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas.
    Esther Latres, Marija Drobnjak, Daphna M. Pollack, Maria Rosario Oliva, M Ramos, Martin S. Karpeh, James M. Woodruff, Carlos Cordon‐Cardo · 1994 · PubMed Central
  62. The Pattern of Signatures in Gastric Cancer Prognosis
    Julita Machlowska, Ryszard Maciejewski, Robert Sitarz · 2018 · International Journal of Molecular Sciences
  63. NMR structure of a complex between MDM2 and a small molecule inhibitor
    David C. Fry, S. Donald Emerson, Stefan Palme, Binh Thanh Vu, Chao‐Min Liu, Frank Podlaski · 2004 · Journal of Biomolecular NMR
  64. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer
    Ming Yang, Y. Guo, Xiaojie Zhang, Xiaoping Miao, W. Tan, Tong Sun, Dan Zhao, Dianke Yu, Jian Li, Dongxin Lin · 2007 · Carcinogenesis
  65. 30 years and a long way into p53 research
    Pierre L. Hainaut, Klas G. Wiman · 2009 · The Lancet Oncology
  66. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.
    J Keleti, Martha Quezado, M M Abaza, Mark A. Raffeld, Maria Tsokos · 1996 · Europe PMC (PubMed Central)
  67. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours
    Frank Courjal, Marguerite Cuny, C Rodriguez, Geneviève Louason, Paul Speiser, Dionyssios Katsaros, Minna Tanner, Robert Zeillinger, Charles G. Theillet · 1996 · British Journal of Cancer
  68. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated.
    Pamela McKenzie, Sylvie Mireille Guichard, David S. Middlemas, Richard A. Ashmun, Mary K. Danks, Linda C. Harris · 1999 · PubMed
  69. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions
    Y. SOINI, D Kamel, Paavo K. Pääkkö, V.-P. Lehto, A Oikarinen, Kirsi Vähäkangas · 2006 · British Journal of Dermatology
  70. Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression
    Lihong Chen, Wenge Lu, Sudhir Agrawal, Wenqiang Zhou, Ruiwen Zhang, Jiandong Chen · 1999 · Molecular Medicine
  71. LYAR, a novel nucleolar protein with zinc finger DNA-binding motifs, is involved in cell growth regulation.
    L Su, R. Jane Hershberger, Irving L. Weissman · 1993 · Genes & Development
  72. p53 Controls Autoimmune Arthritis via STAT‐Mediated Regulation of the Th17 Cell/Treg Cell Balance in Mice
    Jin‐Sil Park, Mi‐Ae Lim, Mi‐La Cho, Jun‐Geol Ryu, Young‐Mee Moon, JooYeon Jhun, Jae Kyeong Byun, Eun‐Kyung Kim, Sue‐Yun Hwang, Ji Hyeon Ju et al. · 2012 · Arthritis & Rheumatism
  73. Molecular aspects of esophageal squamous cell carcinoma carcinogenesis
    Dárcio Matenhauer Lehrbach, Marcelo Eidi Nita, Ivan Cecconello · 2003 · Arquivos de Gastroenterologia
  74. CDKN2A germline splicing mutation affecting both p16ink4 and p14arf RNA processing in a melanoma/neurofibroma kindred
    Fiorella Petronzelli, Danila Sollima, Giuseppe Coppola, Maria Enrica Martini‐Neri, Giovanni Neri, Maurizio Genuardi · 2001 · Genes Chromosomes and Cancer
  75. Physical and Functional Interactions between PML and MDM2
    Xiaolong Wei, Zhong Kang Yu, Arivudainambi Ramalingam, Steven R. Grossman, Yu Jiang, Donald B. Bloch, Carl G. Maki · 2003 · Journal of Biological Chemistry
  76. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population
    Zhibin Hu, Hongxia Ma, Jin Li, Ji Qian, Jian-Nong Zhou, Yijiang Chen, Lin Xu, Xinru Wang, Qingyi Wei, Hongbing Shen · 2005 · International Journal of Cancer
  77. Induction of the p53-target gene GADD45 in HPV-positive cancer cells
    Karin Butz, Noel J. Whitaker, Claudia Denk, Angela Ullmann, Caroline Geisen, Felix Hoppe‐Seyler · 1999 · Oncogene
  78. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells.
    Jean M. Gudas, H Nguyen, Regina C. Klein, Dai Katayose, Prem K. Seth, Kenneth H. Cowan · 1995 · PubMed
  79. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia.
    Gianluca Gaïdano, Elizabeth W. Newcomb, Jerry Z. Gong, Vittorio Tassi, Antonino Neri, Agostino Cortelezzi, Rossella Calori, Luca Baldini, Riccardo Dalla‐Favera · 1994 · PubMed Central
  80. Inhibition of Serum- and Calcium-Induced Differentiation of Human Keratinocytes by HPV16 E6 Oncoprotein: Role of p53 Inactivation
    Levana Sherman, Anna Jackman, Hagar Itzhaki, Melissa C. Stoppler, Debbie Koval, Richard Schlegel · 1997 · Virology
  81. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications
    S. Agarwal · 1999 · Oral Oncology
  82. Enhanced DNA binding capacity on up‐regulated epidermal wild‐type p53 in vitiligo by H 2 O 2 ‐mediated oxidation: a possible repair mechanism for DNA damage
    Mohamed M. A. E. L. Salem, Mohammad Shalbaf, Nicholas C.J. Gibbons, Bhaven Chavan, Margaret Julie Thornton, Karin Uta Schallreuter · 2009 · The FASEB Journal
  83. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.
    Arturo Chávez‐Reyes, John M. Parant, Lisa L. Amelse, Roberto Montes de Oca Luna, Stanley J. Korsmeyer, Guillermina Lozano · 2003 · PubMed
  84. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)
    Dorota Dworakowska B, Ewa Jassem, Jacek Jassem, Brigitte Peters, Rafał Dziadziuszko, Maciej Żylicz, Joanna Jakóbkiewicz‐Banecka, Grażyna Kobierska‐Gulida, Amelia Szymanowska, Jan Skokowski et al. · 2003 · Lung Cancer
  85. Aberrant ubiquitin-mediatedproteolysis of cell cycle regulatory proteins and oncogenesis
    Tarig Bashir, Michele Pagano · 2003 · Advances in cancer research
  86. Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
    Wang, Shaomeng, Zhao, Yujun, Bernard, Denzil, Aguilar, Angelo, Kumar, Sanjeev · 2012 · Topics in Medicinal Chemistry
  87. TP53 allele loss, mutations and expression in malignant melanoma
    Viví Ann Flørenes, Tove Øyjord, R Holm, M Skrede, A-L Børresen, J. M. Nesland, Øystein Fodstad · 1994 · British Journal of Cancer
  88. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
    Yi, Hanjie, Yan, Xianglei, Luo, Qiuyun, Yuan, Luping, Li, Baoxia, Pan, Wentao, Zhang, Lin, Chen, Haibo, Wang, Jing, Zhang, Yubin et al. · 2018 · Journal of Experimental &amp; Clinical Cancer Research
  89. Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP
    Yajie Chen, Qian Hao, Shanshan Wang, Mingming Cao, Yingdan Huang, Xiaoling Weng, Jieqiong Wang, Zhen Zhang, Xianghuo He, Hua Lu et al. · 2021 · Proceedings of the National Academy of Sciences
  90. Beyond effector caspase inhibition
    Alexander H. Stegh, Ronald Anthony DePinho · 2011 · Cell Cycle
  91. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer
    Ji‐Youn Han, Geon Kook Lee, Dae Ho Jang, Sungyoung Lee, Jin Soo Lee · 2008 · Cancer
  92. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression—transcriptional induction of p21WAF1 and p27kip1 by inhibition of PI-3K/AKT pathway
    Hee‐Jung Choi, Tae‐Wook Chung, Sung‐Koo Kang, Young‐Choon Lee, Jeong‐Heon Ko, Jong-Guk Kim, Cheorl‐Ho Kim · 2006 · Glycobiology
  93. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma
    Avery A. Sandberg · 2005 · Cancer Genetics and Cytogenetics
  94. Alteration of G1 cell-cycle protein expression and induction of p53 but not p21/waf1 by the DNA-modifying carcinogen 2-acetylaminofluorene in growth-stimulated hepatocytes in vitro
    Birgitte Lindeman, Ellen Skarpen, G. Hege Thoresen, Thoralf Christoffersen, Lene Wier�d, Inger Helene Madshus, Henrik Sverre Huitfeldt · 1999 · Molecular Carcinogenesis
  95. p53 Expression and DNA ploidy of cartilage lesions
    Brendan Coughlan, Aaron Feliz, Tsuyoshi Ishida, Bogdan A. Czerniak, Howard D. Dorfman · 1995 · Human Pathology
  96. p76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53
    Mary Ellen Perry, Susan M. Mendrysa, Leslie J. Saucedo, Paul Tannous, Marisa K. Holubar · 2000 · Journal of Biological Chemistry
  97. TP53 Tumor Suppressor Gene and Skin Carcinogenesis.
    Nicole Basset‐Séguin, Jean‐Pierre Molès, Valérie Mils, O. Dereure, Jean‐Jacques Guilhou · 1994 · Journal of Investigative Dermatology
  98. Transactivation of the P2 promoter of parathyroid hormone-related protein by human T-cell lymphotropic virus type I Tax1: evidence for the involvement of transcription factor Ets1
    J Dittmer, Scott D. Gitlin, Robert L. Reid, John N Brady · 1993 · Journal of Virology
  99. Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions
    Tingting Zhang, Carol L. Prives · 2001 · Journal of Biological Chemistry
  100. Amplification of the cyclin-dependent kinase 4 ( CDK4 ) gene is associated with high cdk4 protein levels in glioblastoma multiforme
    Britta Rollbrocker, Andreas Waha, David N. Louis, Otmar D. Wiestler, Andreas von Deimling · 1996 · Acta Neuropathologica